PRODUCTS

Ocular Allergy POC Assay

The only non-invasive, rapid Point-of-Care (POC) test for Ocular Allergy including Allergic Conjunctivitis (AC)

Every year, millions of people visit their doctors seeking relief from “pink eye”, also known as ocular conjunctivitis. The diagnosis can be difficult because the symptoms are often the same whether the cause is a virus, bacterium, or allergen. The Allereye® Tear Total IgE Test helps physicians make a quick and confident diagnosis. The Allergic Conjunctivitis diagnosis can prevent unnecessary dry-eye treatment and/or antibiotic prescription.

Allereye is CE Marked and FDA Cleared, but is not yet available for sale in the United States.

HIV Screening and Confirmatory Assays

Bluejay Diagnostics is pleased to offer safe, accessible urine-based HIV-1 assays – the Calypte HIV-1 Urine EIA Kit for HIV-1 screening and the Cambridge Biotech HIV-1 Western Blot Kit for HIV-1 confirmation.


PRODUCTS IN DEVELOPMENT

Bluejay Diagnostics is leveraging its proprietary technology platform to develop innovative new products. Click the “Read More” button to learn more.



TECHNOLOGY PLATFORM

Bluejay’s proprietary platform technology is based on a combination of well-established immunochromatography and laminar flow methodologies.


About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. develops, manufactures and markets easy-to-use, point-of-care medical diagnostics tests. The company offers multiple FDA-Cleared non-invasive, affordable products.



NEWS

Allereye Tear Total IgE Kit

April 9, 2019

BLUEJAY DIAGNOSTICS, INC. ANNOUNCES CE MARK FOR ITS ALLEREYE® TEAR TOTAL IGE TEST

Bluejay Diagnostics, Inc. (Bluejay) is pleased to announce that it has received CE Mark for the Allereye® Tear Total IgE Test. Allereye, an FDA-Cleared point-of-care (POC) device, offers healthcare providers a cost-effective, non-invasive, reliable, easy-to-use solution to aid in the diagnosis of allergic conjunctivitis.


April 1, 2019

BLUEJAY DIAGNOSTICS, INC. AND U.S. NAVY ENTER COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT TO DEVELOP NON-INVASIVE POINT-OF-CARE TESTS FOR LYME DISEASE

The project, which will take place in Maryland, will investigate and develop a non-invasive point-of-care test for Lyme disease with the goal of improving detection of Lyme disease at an early stage.